Black Diamond Therapeutics

Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass. and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.

Black Diamond Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the presentation of pre-clinical data on the Company's lead product candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020).

Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium

Black Diamond is an innovative cancer drug-developer using genetic sequencing to identify families of allosteric mutations, and developing drug molecules to inhibit their proliferation. The company raised >$200m via a January IPO, and shares have traded at a substantial premium to IPO price ever since.

Black Diamond Therapeutics: One To Watch In Precision Oncology Space

CAMBRIDGE, Mass. and NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that pre-clinical data on the Company’s lead product candidate BDTX-189 will be presented at the 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020) taking place October 24-25, 2020.

Black Diamond Therapeutics to Present Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium

CAMBRIDGE, Mass. and NEW YORK, Sept.  29, 2020  (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Robert A. Ingram as the Chairman of its Board of Directors. Brad Bolzon, Ph.D., Chairman and Managing Director at Versant Ventures and Black Diamond’s founding Chairman, will remain on the Company’s board.

Black Diamond Therapeutics Announces the Appointment of Biopharmaceutical Veteran Robert A. Ingram as Chairman of the Board

CAMBRIDGE, Mass. and NEW YORK, Sept.  10, 2020  (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the Morgan Stanley 18th Annual Global Healthcare Conference. The presentation will take place on Tuesday, September 15, 2020, at 2:45 PM ET.

Black Diamond Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference

Dr. Humphrey brings more than 20 years of experience as a leader in oncology drug development Dr. Humphrey brings more than 20 years of experience as a leader in oncology drug development

Black Diamond Therapeutics Announces the Appointment of Rachel Humphrey, M.D., as Chief Medical Officer

CAMBRIDGE, Mass. and NEW YORK, Aug.  11, 2020  (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today reported financial results for the second quarter ended June 30, 2020, and provided a corporate update.

Black Diamond Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Black Diamond Therapeutics (BDTX) This Earnings Season?

CAMBRIDGE, Mass. and NEW YORK, Aug.  04, 2020  (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Fang Ni, Pharm.D., as Chief Business Officer.

Black Diamond Therapeutics Announces the Appointment of Fang Ni as Chief Business Officer

CAMBRIDGE, Mass. and NEW YORK, July  28, 2020  (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to BDTX-189 for the treatment of adult patients with solid tumors harboring an allosteric human epidermal growth factor receptor 2 (HER2) mutation or an epidermal growth factor receptor (EGFR) or HER2 Exon 20 insertion mutation who have progressed following prior treatment and who have no satisfactory treatment options. BDTX-189, an orally available, irreversible small molecule inhibitor, is the Company’s lead product candidate designed to selectively inhibit the activity of a broad range of previously unaddressed oncogenic driver mutations of the ErbB kinases in EGFR and HER2.

Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of Adult Patients with a Solid Tumor Harboring an Allosteric HER2 Mutation or an EGFR or HER2 Exon 20 Insertion Mutation

CAMBRIDGE, Mass. and NEW YORK, June  16, 2020  (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s business at the BMO 2020 Prescriptions for Success Healthcare Conference. The presentation will take place on Tuesday, June 23, 2020, at 2:00 PM ET.

Black Diamond Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

Black Diamond Therapeutics (BDTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Black Diamond Therapeutics (BDTX) Stock Stands Out in a Strong Industry

CAMBRIDGE, Mass. and NEW YORK, May  12, 2020  (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today reported financial results for the first quarter ended March 31, 2020, and provided a corporate update.

Black Diamond Therapeutics Reports First Quarter 2020 Financial Results and Corporate Update

Minerva Neurosciences

Sprout Social

ThermoGenesis Holdings, Inc

Zynex Inc

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

5 Stocks With Recent Price Strength Amid Disappointing Data

As of late, it has definitely been a great time to be an investor in Black Diamond Therapeutics, Inc. (BDTX).

Black Diamond Therapeutics, Inc. (BDTX) Shares March Higher, Can It Continue?

1Life Healthcare

Reynolds Consumer Products

Arcutis Biotherapeutics

These four companies just made their debuts. Should they be on your radar?

How Did Last Week's IPOs Perform?

CAMBRIDGE, Mass. and NEW YORK, Feb.  03, 2020  (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the closing of its initial public offering of 12,174,263 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, at a public offering price of $19.00 per share. The aggregate gross proceeds to Black Diamond from the offering were approximately $231.3 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Black Diamond. Black Diamond’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “BDTX.”

Black Diamond Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Black Diamond Therapeutics (NASDAQ: BDTX) made its public debut Thursday morning, opening at $33 after being priced at $19 per share.

Black Diamond Therapeutics Opens Well Above IPO Price

News for Black Diamond Therapeutics Stock (BDTX)